Eli Lilly Reports Strong Third-Quarter 2026 Financial Results

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year and above analyst expectations of $22.58 billion, while adjusted earnings per share were $7.48 versus $5.68 expected. Mounjaro sales rose 65% to $10.72 billion and Zepbound sales increased 49% to $5.35 billion, driving growth. The company raised its full-year revenue guidance to $91 billion–$92 billion from $85 billion–$87 billion and set adjusted EPS guidance at $35–$36, reflecting adjustments for acquired in-process R&D charges.